RVNC News and Press, Revance Therapeutics Inc. From 11/08/23

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Revance Therapeutics Inc. (RVNC) is expected to report $-1.1 for Q3 2023

2023-11-07 13:09:35 ET Revance Therapeutics ( NASDAQ: RVNC ) is scheduled to announce Q3 earnings results on Wednesday, November 8th, after market close. The consensus EPS Estimate is -$0.94 and the consensus Revenue Estimate is $58.74M (+102.6% Y/Y). Over the last 3 m...

2023-11-02 04:19:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund was down 5.4% during Q3, which was 2.0% better than the Benchmark...

Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding...

2023-10-27 15:22:19 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans AbbVie: The Humira Loss May Be Fully Priced In After All AbbVie stock...

- DAXXIFY® (daxibotulinumtoxinA-lanm) for Injection named to TIME’s list of the best inventions of 2023. - DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation in neuromodulator formulation in more than 30 years. TIME®...

2023-10-19 17:11:44 ET Gainers: PacWest Bancorp ( PACW ) +7% . Biomea Fusion ( BMEA ) +5% . Bank OZK ( OZK ) +3% . ADMA Biologics ( ADMA ) +3% . Revance Therapeutics ( RVNC ) +3% . Losers: SolarEdge Technologies ( SEDG ...

NEW YORK, NY / ACCESSWIRE / September 26, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC). Investors who purchased Revance securities are encouraged to obtain addition...

2023-09-24 13:01:04 ET The growing popularity of GLP-1 weight-loss drugs may be already impacting demand for certain procedures like body contouring and dermo fillers, according to Needham’s Q3 aesthetics procedures survey. Needham asked respondents who were familiar with GLP-1 d...